Recent Insider Transactions • Jul 17
Director recently bought kr494k worth of stock On the 16th of July, Jens Viebke bought around 3k shares on-market at roughly kr195 per share. This transaction amounted to 84% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr6.7m more in shares than they bought in the last 12 months. Reported Earnings • Jul 17
Second quarter 2026 earnings released Second quarter 2026 results: Revenue: kr355.7m (up 25% from 2Q 2025). Net income: kr81.9m (up 54% from 2Q 2025). Profit margin: 23% (up from 19% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 2.8% decline forecast for the Biotechs industry in the United Kingdom. Announcement • Jun 16
Bonesupport Holding AB (publ) (OM:BONEX) commences an Equity Buyback Plan for own shares, under the authorization approved on May 12, 2026. Bonesupport Holding AB (publ) (OM:BONEX) commences share repurchases on June 9, 2026, under the program mandated by the shareholders in the Annual General Meeting held on May 12, 2026. As per the mandate, the company is authorized to repurchase own shares, representing does not exceed 10% of its issued share capital at any point of time. The shares will be repurchased at a price which falls within the prevailing price interval registered at each point in time (i.e. in the interval between the highest purchase price and the lowest selling price). The purpose of the proposed authorizations, and the reason for deviating from the shareholders' preferential rights with regard to transfer of own shares, is to enable acquisition financing through the utilization of own ordinary shares, to give the Board of Directors the opportunity to continuously adapt the company's capital structure to the company's capital needs and thereby contribute to increased shareholder value, and to give the company the opportunity to divest shares in its own holding for cash flow hedging of social security costs arising from the delivery of shares to participants in the incentive program resolved by the Annual General Meeting 2023 (LTI 2023).The ordinary shares shall be made in cash. The repurchased shares will be cancelled by resolution of upcoming Annual General Meetings. The program is valid until the next Annual General Meeting in 2027.
On June 8, 2026, the company announced a share repurchase program. Under the program, the company will repurchase up to 373,320 shares for SEK 100 million. The ordinary shares shall be made in cash. The program will commence from June 9, 2026 and be valid till July 9, 2026. Recent Insider Transactions • Jun 01
Director recently bought kr200k worth of stock On the 27th of May, Jens Viebke bought around 844 shares on-market at roughly kr237 per share. This transaction amounted to 39% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr346k. Despite this recent purchase, insiders have collectively sold kr6.4m more in shares than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to kr220, the stock trades at a forward P/E ratio of 41x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 82% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr409 per share. Recent Insider Transactions • May 19
Independent Chairman of the Board recently bought kr346k worth of stock On the 12th of May, Lennart Johansson bought around 2k shares on-market at roughly kr231 per share. This transaction amounted to 1.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Lennart has been a net seller over the last 12 months, reducing personal holdings by kr7.7m. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to kr214, the stock trades at a forward P/E ratio of 40x. Average trailing P/E is 12x in the Biotechs industry in the United Kingdom. Total returns to shareholders of 115% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr419 per share. Reported Earnings • Apr 21
Full year 2025 earnings released: EPS: kr2.16 (vs kr2.04 in FY 2024) Full year 2025 results: EPS: kr2.16 (up from kr2.04 in FY 2024). Revenue: kr1.17b (up 31% from FY 2024). Net income: kr142.2m (up 6.3% from FY 2024). Profit margin: 12% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.4% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 09
Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026 Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026, at 10:00 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund Sweden Reported Earnings • Feb 27
Full year 2025 earnings released: EPS: kr2.16 (vs kr2.04 in FY 2024) Full year 2025 results: EPS: kr2.16 (up from kr2.04 in FY 2024). Revenue: kr1.17b (up 31% from FY 2024). Net income: kr142.2m (up 6.3% from FY 2024). Profit margin: 12% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 4.4% decline forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 30% per year. New Risk • Jan 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jan 14
Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026 Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024.
For the year, the company expected sales growth above 35% at constant exchange rates. Reported Earnings • Oct 24
Third quarter 2025 earnings released: EPS: kr0.52 (vs kr0.47 in 3Q 2024) Third quarter 2025 results: EPS: kr0.52 (up from kr0.47 in 3Q 2024). Revenue: kr294.1m (up 24% from 3Q 2024). Net income: kr34.5m (up 13% from 3Q 2024). Profit margin: 12% (down from 13% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Announcement • Sep 16
Bonesuport Announces Positive Results from A Clinical Study Demonstrating Significantly Improved Patient-Based Outcomes for Cerament®? G in Single-Stage Revision Surgery for Patients Patients Lining from Periprosthetic Joint Infection Bonesuport announced positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT®? G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meting, 11-13 September 2025. The prospective clinical study conducted at Charite - Universitatsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS). According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later. The study (CeraHip) is expected to be published during the autumn. New Risk • Aug 01
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: kr8.4m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Significant insider selling over the past 3 months (kr8.4m sold). Buy Or Sell Opportunity • Aug 01
Now 21% undervalued Over the last 90 days, the stock has risen 4.3% to kr323. The fair value is estimated to be kr408, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 84% in 2 years. Earnings are forecast to grow by 288% in the next 2 years. Recent Insider Transactions • Jul 31
Independent Chairman of the Board recently bought kr398k worth of stock On the 28th of July, Lennart Johansson bought around 1k shares on-market at roughly kr330 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr460k. This was Lennart's only on-market trade for the last 12 months. Reported Earnings • Jul 16
Second quarter 2025 earnings released: EPS: kr0.81 (vs kr0.42 in 2Q 2024) Second quarter 2025 results: EPS: kr0.81 (up from kr0.42 in 2Q 2024). Revenue: kr284.4m (up 29% from 2Q 2024). Net income: kr53.1m (up 94% from 2Q 2024). Profit margin: 19% (up from 13% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 67% per year and the company’s share price has also increased by 67% per year. Recent Insider Transactions • Jun 08
Chief Executive Officer recently bought kr460k worth of stock On the 4th of June, Emil Billbäck bought around 2k shares on-market at roughly kr256 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Emil has been a net seller over the last 12 months, reducing personal holdings by kr78m. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 24
Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025 Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Location: to be held at elite hotel ideon, scheelevagen 27, lund Sweden Reported Earnings • Apr 18
Full year 2024 earnings released: EPS: kr2.04 (vs kr3.77 in FY 2023) Full year 2024 results: EPS: kr2.04 (down from kr3.77 in FY 2023). Revenue: kr898.7m (up 52% from FY 2023). Net income: kr133.8m (down 45% from FY 2023). Profit margin: 15% (down from 42% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 93% per year whereas the company’s share price has increased by 90% per year. Announcement • Apr 01
Bonesupport Holding AB (Publ) Files FDA Submission for Cerament V BonesUPPORT announced that the company has submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT® V (vancomycin), with the Food and Drug Administration (FDA), for the indication bone infection. The market approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. The clinical data, from several published studies, demonstrated that CERAMENT G is superior to previous standard options in managing bone infections. With market authorization for CERAMENT V, physicians would be equipped with an additional tool to manage bone infections, primarily caused by Methicillin-Resistant Staphylococcus eg. MRSA or MRSE. CERAMENT V in Europe, where the product has had market approval for several years, represents 15% of the sales of antibiotic-releasing products. Bone grafts with local antibiotic release have proven to be a very important tool in the ambition to drastically reduce the need for systemic antibiotic use and combat antibiotic resistance. CERAMENT V has previously received the categorization of "breakthrough device" for the indication of bone infection from the FDA. Reported Earnings • Feb 27
Full year 2024 earnings released: EPS: kr2.04 (vs kr3.77 in FY 2023) Full year 2024 results: EPS: kr2.04 (down from kr3.77 in FY 2023). Revenue: kr898.7m (up 52% from FY 2023). Net income: kr133.8m (down 45% from FY 2023). Profit margin: 15% (down from 42% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has increased by 111% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Jan 09
Now 21% undervalued Over the last 90 days, the stock has risen 14% to kr363. The fair value is estimated to be kr460, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 48% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 105% in 2 years. Earnings are forecast to grow by 405% in the next 2 years. Announcement • Jan 08
Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot Ulcers Bonesupport Holding AB (publ) announced strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, versus 55.1%, p<0.00001]. Announcement • Nov 29
Bonesupport Holding AB (publ) Announces Nomination Committee Changes The composition of BONESUPPORT's Nomination Committee ahead of the 2025 Annual General Meeting was announced in the company's interim report for the third quarter on October 24 2024. As a result of a subsequent change in ownership, the composition of the Nomination Committee has changed with Anna Sundberg (appointed by Handelsbanken Fonder) leaving the Nomination Committee and Erik Selin (appointed by Erik Selin Fastigheter AB) joining as a new member of the Nomination Committee. Accordingly, the Nomination Committee ahead of the 2025 Annual General Meeting consists of the following members: Caroline Sjösten, appointed by Swedbank Robur Fonder; Erik Selin, appointed by Erik Selin Fastigheter; and Staffan Lindstrand, appointed by HealthCap. In addition, the Chairman of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the Nomination Committee. The Nomination Committee has appointed Caroline Sjösten as Committee chair. Recent Insider Transactions • Nov 21
Insider recently sold kr10m worth of stock On the 19th of November, Michael Diefenbeck sold around 30k shares on-market at roughly kr335 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth kr60m. Insiders have been net sellers, collectively disposing of kr128m more than they bought in the last 12 months. Announcement • Oct 31
Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB. Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB for SEK 1.3 billion on October 30, 2024. In this transaction, Erik Selin will acquire 3.9 million shares at a rate of SEK 325.
Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB on October 30, 2024. Recent Insider Transactions • Oct 27
Insider recently sold kr690k worth of stock On the 25th of October, Annelie Vikner sold around 2k shares on-market at roughly kr345 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr51m more than they bought in the last 12 months. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: kr0.47 (vs kr3.52 in 3Q 2023) Third quarter 2024 results: EPS: kr0.47 (down from kr3.52 in 3Q 2023). Revenue: kr237.5m (up 50% from 3Q 2023). Net income: kr30.6m (down 87% from 3Q 2023). Profit margin: 13% (down from 145% in 3Q 2023). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has increased by 109% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Aug 05
Now 20% undervalued Over the last 90 days, the stock has risen 17% to kr268. The fair value is estimated to be kr336, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 115% in 2 years. Earnings are forecast to grow by 49% in the next 2 years. Recent Insider Transactions • Jul 17
Chief Executive Officer recently sold kr18m worth of stock On the 11th of July, Emil Billbäck sold around 63k shares on-market at roughly kr291 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Emil's only on-market trade for the last 12 months. Reported Earnings • Jul 12
Second quarter 2024 earnings released: EPS: kr0.42 (vs kr0.08 in 2Q 2023) Second quarter 2024 results: EPS: kr0.42 (up from kr0.08 in 2Q 2023). Revenue: kr219.8m (up 57% from 2Q 2023). Net income: kr27.4m (up 427% from 2Q 2023). Profit margin: 13% (up from 3.7% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Jun 02
Key Executive recently sold kr3.6m worth of stock On the 27th of May, Michael Mortensen sold around 14k shares on-market at roughly kr260 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Michael has been a net seller over the last 12 months, reducing personal holdings by kr3.2m. Recent Insider Transactions • May 06
Insider recently sold kr917k worth of stock On the 30th of April, Michael Diefenbeck sold around 4k shares on-market at roughly kr229 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr2.9m more than they bought in the last 12 months. Recent Insider Transactions • May 01
Insider recently sold kr478k worth of stock On the 26th of April, Michael Diefenbeck sold around 2k shares on-market at roughly kr239 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr2.0m more than they bought in the last 12 months. Reported Earnings • Apr 22
Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022) Full year 2023 results: EPS: kr3.77 (up from kr1.06 loss in FY 2022). Revenue: kr591.1m (up 80% from FY 2022). Net income: kr245.0m (up kr313.2m from FY 2022). Profit margin: 42% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth. Announcement • Feb 23
Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs BONESUPPORT AB announced a change in its management team. Kristina Ingvar will leave BONESUPPORT and her role as Executive Vice President Quality Management & Regulatory Affairs (EVP QM&RA). The change is effective as per 22 March 2024. She will take up a position as Corporate Vice President in the global healthcare company Novo Nordisk. Recruitment for the position EVP QM&RA has been initiated. Reported Earnings • Feb 17
Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022) Full year 2023 results: EPS: kr3.77 (up from kr1.06 loss in FY 2022). Revenue: kr591.1m (up 80% from FY 2022). Net income: kr245.0m (up kr313.2m from FY 2022). Profit margin: 42% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 17
Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022) Full year 2023 results: EPS: kr3.77 (up from kr1.06 loss in FY 2022). Revenue: kr591.1m (up 80% from FY 2022). Net income: kr245.0m (up kr313.2m from FY 2022). Profit margin: 42% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Dec 18
Independent Director recently bought kr1.0m worth of stock On the 14th of December, Mary O’Connor bought around 6k shares on-market at roughly kr170 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr21m more in shares than they bought in the last 12 months. Announcement • Nov 29
Bonesupport Holding AB Provides Sales Guidance for the Year 2024 Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency). Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to kr149, the stock trades at a forward P/E ratio of 71x. Average forward P/E is 26x in the Biotechs industry in Europe. Total returns to shareholders of 143% over the past three years. Reported Earnings • Oct 28
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr158.2m (up 87% from 3Q 2022). Net income: kr228.8m (up kr243.7m from 3Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 36% per year. Announcement • Oct 17
Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection BONESUPPORTTM announced that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA). The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma. Recent Insider Transactions • Aug 02
Independent Director recently bought kr1.1m worth of stock On the 26th of July, Mary O’Connor bought around 7k shares on-market at roughly kr145 per share. This transaction amounted to 62% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr36m more in shares than they bought in the last 12 months. Recent Insider Transactions • Jul 16
Insider recently bought kr426k worth of stock On the 14th of July, Michael Mortensen bought around 3k shares on-market at roughly kr142 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr604k. Despite this recent purchase, insiders have collectively sold kr44m more in shares than they bought in the last 12 months. Breakeven Date Change • Jul 14
Forecast to breakeven in 2023 The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr19.8m in 2023. Earnings growth of 107% is required to achieve expected profit on schedule. Reported Earnings • Jul 14
Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022) Second quarter 2023 results: EPS: kr0.08 (up from kr0.25 loss in 2Q 2022). Revenue: kr140.4m (up 88% from 2Q 2022). Net income: kr5.21m (up kr21.5m from 2Q 2022). Profit margin: 3.7% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 41% per year. Announcement • May 26
BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures BONESUPPORT Holding AB announced the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company's antibiotic-eluting bone graft CERAMENT G. The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection. The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%. Recent Insider Transactions • May 17
Insider recently sold kr701k worth of stock On the 12th of May, Annelie Vikner sold around 7k shares on-market at roughly kr108 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth kr15m. Insiders have been net sellers, collectively disposing of kr43m more than they bought in the last 12 months. Breakeven Date Change • May 15
Forecast breakeven date moved forward to 2023 The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr15.7m in 2023. Earnings growth of 103% is required to achieve expected profit on schedule. Recent Insider Transactions • May 06
Chief Executive Officer recently sold kr15m worth of stock On the 28th of April, Emil Billbäck sold around 146k shares on-market at roughly kr100 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Emil has been a net seller over the last 12 months, reducing personal holdings by kr21m. Reported Earnings • Apr 24
Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021) Full year 2022 results: kr1.06 loss per share (improved from kr1.34 loss in FY 2021). Revenue: kr328.8m (up 55% from FY 2021). Net loss: kr68.2m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Recent Insider Transactions • Mar 17
Insider recently sold kr1.4m worth of stock On the 14th of March, Fergus MacLeod sold around 17k shares on-market at roughly kr79.03 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr22m more than they bought in the last 12 months. Reported Earnings • Feb 18
Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021) Full year 2022 results: kr1.06 loss per share (improved from kr1.34 loss in FY 2021). Revenue: kr328.8m (up 55% from FY 2021). Net loss: kr68.2m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year. Recent Insider Transactions • Jan 01
Director recently bought kr203k worth of stock On the 28th of December, Mary O’Connor bought around 3k shares on-market at roughly kr80.33 per share. This transaction amounted to 85% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr21m more in shares than they bought in the last 12 months. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Christine Rankin was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr84.6m (up 54% from 3Q 2021). Net loss: kr15.0m (loss widened 6.3% from 3Q 2021). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Breakeven Date Change • Oct 26
No longer forecast to breakeven The 2 analysts covering Bonesupport Holding no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr2.62m in 2023. New consensus forecast suggests the company will make a loss of kr22.7m in 2023. Reported Earnings • Jul 15
Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021) Second quarter 2022 results: kr0.25 loss per share (up from kr0.42 loss in 2Q 2021). Revenue: kr74.6m (up 44% from 2Q 2021). Net loss: kr16.3m (loss narrowed 40% from 2Q 2021). Over the next year, revenue is forecast to grow 37%, compared to a 11% growth forecast for the industry in the United Kingdom. Recent Insider Transactions • Jun 14
Insider recently bought kr101k worth of stock On the 8th of June, Lars Lindgren bought around 2k shares on-market at roughly kr63.00 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.2m. Insiders have collectively bought kr4.0m more in shares than they have sold in the last 12 months. Breakeven Date Change • Jun 01
Forecast breakeven date moved forward to 2023 The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 26% to 2022. The company is expected to make a profit of kr2.70m in 2023. Average annual earnings growth of 112% is required to achieve expected profit on schedule. Breakeven Date Change • May 18
Forecast breakeven date pushed back to 2024 The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 80% per year to 2023. The company is expected to make a profit of kr185.0m in 2024. Average annual earnings growth of 110% is required to achieve expected profit on schedule. Recent Insider Transactions • May 12
Chairman of the Board recently bought kr1.2m worth of stock On the 9th of May, Lennart Johansson bought around 30k shares on-market at roughly kr41.40 per share. This was the largest purchase by an insider in the last 3 months. Lennart has been a buyer over the last 12 months, purchasing a net total of kr2.8m worth in shares. Breakeven Date Change • May 09
Forecast breakeven date pushed back to 2024 The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 30% per year to 2023. The company is expected to make a profit of kr185.0m in 2024. Average annual earnings growth of 83% is required to achieve expected profit on schedule. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Tone Kvale was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 15
Full year 2021 earnings released: kr1.34 loss per share (vs kr1.72 loss in FY 2020) Full year 2021 results: kr1.34 loss per share (up from kr1.72 loss in FY 2020). Revenue: kr212.9m (up 18% from FY 2020). Net loss: kr85.5m (loss narrowed 16% from FY 2020). Over the next year, revenue is forecast to grow 43%, compared to a 17% growth forecast for the pharmaceuticals industry in the United Kingdom. Breakeven Date Change • Feb 20
Forecast breakeven date pushed back to 2024 The 2 analysts covering Bonesupport Holding previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 34% per year to 2023. The company is expected to make a profit of kr135.5m in 2024. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr1.31 loss per share (up from kr1.72 loss in FY 2020). Revenue: kr212.9m (up 18% from FY 2020). Net loss: kr85.5m (loss narrowed 16% from FY 2020). Revenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 42%, compared to a 16% growth forecast for the pharmaceuticals industry in the United Kingdom. Recent Insider Transactions • Dec 08
Insider recently bought kr182k worth of stock On the 3rd of December, Fergus MacLeod bought around 5k shares on-market at roughly kr36.40 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr343k. Insiders have collectively bought kr3.4m more in shares than they have sold in the last 12 months. Executive Departure • Dec 01
Executive Vice President of Manufacturing & Supply Johan Olsson has left the company On the 1st of December, Johan Olsson's tenure as Executive Vice President of Manufacturing & Supply ended. As of September 2021, Johan still personally held only 3.46k shares (kr138k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.67 years. Executive Departure • Dec 01
Executive VP of Medical & Clinical Affairs and Chief Medical Officer Michael Diefenbeck has left the company On the 1st of December, Michael Diefenbeck's tenure as Executive VP of Medical & Clinical Affairs and Chief Medical Officer ended after 4.7 years in the role. As of September 2021, Michael still personally held 26.70k shares (kr1.1m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.67 years. Reported Earnings • Nov 06
Third quarter 2021 earnings released The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr54.9m (up 14% from 3Q 2020). Net loss: kr14.1m (loss narrowed 34% from 3Q 2020). Breakeven Date Change • Sep 23
Forecast to breakeven in 2023 The 2 analysts covering Bonesupport Holding expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr83.0m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule. Recent Insider Transactions • Sep 22
Chief Executive Officer recently bought kr343k worth of stock On the 13th of September, Emil Billbäck bought around 9k shares on-market at roughly kr38.13 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.6m. Emil has been a buyer over the last 12 months, purchasing a net total of kr751k worth in shares. Breakeven Date Change • Sep 11
Forecast to breakeven in 2023 The analyst covering Bonesupport Holding expects the company to break even for the first time. New forecast suggests the company will make a profit of kr54.0m in 2023. Average annual earnings growth of 101% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 08
Forecast to breakeven in 2023 The analyst covering Bonesupport Holding expects the company to break even for the first time. New forecast suggests the company will make a profit of kr54.0m in 2023. Average annual earnings growth of 101% is required to achieve expected profit on schedule. Recent Insider Transactions • Aug 14
Chief Financial Officer recently bought kr87k worth of stock On the 11th of August, Håkan Johansson bought around 1k shares on-market at roughly kr74.15 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.6m. Håkan has been a buyer over the last 12 months, purchasing a net total of kr521k worth in shares.